Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969865 · ClinicalTrials.gov registry record
Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
A clinical trial of Atherosclerosis, sponsored by Piedmont Healthcare.
- Completed
- Registry status
- 170
- Enrollment target
- 1
- Study location
NCT00969865: Completed study of Atherosclerosis, sponsored by Piedmont Healthcare.
NCT00969865 is a study of Atherosclerosis that has completed, run by Piedmont Healthcare. The registered enrollment target is 170 participants, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00969865, a study of Atherosclerosis, has completed, sponsored by Piedmont Healthcare.
- COMPLETED
- Registry status
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to standard of care) and 2) Individualized Management Group (standard of care plus genetic testing and coronary artery calcium scans).
Conditions Studied
Study Locations (1)
Georgia
- Piedmont Heart Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-12 |
What the finished NCT00969865 record still lists
NCT00969865 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00969865 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00969865 about?
NCT00969865 is a clinical study titled "Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program". This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) S...
What is the current status of trial NCT00969865?
This trial is currently completed. The enrollment target is 170 participants. The study started on 2011-10. Estimated completion is 2016-12.
What conditions does trial NCT00969865 study?
This clinical trial studies the following conditions: Atherosclerosis.
Who is sponsoring clinical trial NCT00969865?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00969865 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00969865's enrollment target sits among peer trials
170 40th of 69 higher than 30 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia